New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
12:34 EDTNFLX, TWTR, AYI, FOLD, REGN, SNY, STAAOn The Fly: Midday Wrap
Stocks on Wall Street were sharply higher at midday in the first trading day of the month and the new quarter. The market has not had such a good start to the second half of a year since 2011. The dayís domestic economic data was generally in-line with expectations, while reports from abroad confirmed that manufacturing expanded last month in China and in the eurozone. ECONOMIC EVENTS: In the U.S., two separate manufacturing readings were released. Markit's manufacturing purchasing manager's index for June had a final reading of 57.3, which was a hair below the 57.5 flash estimate but up from May's 56.4 reading. ISM's manufacturing index slipped very slightly to 55.3 in June from May's 55.4 figure. Construction spending increased 0.1% in May, missing the forecast for 0.5% growth. In China, the purchasing manager's index reading from HSBC and Markit came in at 50.7, which was a bit below the preliminary reading but above the 50 mark that indicates expansion for the first time since December. In Europe, Markit's final eurozone manufacturing PMI for June came in at 51.8, which was down from 52.2 in the prior month and below the earlier flash estimate of 51.9, but still indicated expansion in the sector. COMPANY NEWS: Shares of Netflix (NFLX) climbed 6% after Goldman Sachs upgraded the stock in a note to investors earlier today, predicting that Netflix's total worldwide market will more than double over the next three years and its subscriber growth will continue to exceed expectations... Twitter (TWTR) rose more than 4% after hiring Anthony Noto as its new Chief Financial Officer away from Goldman Sachs (GS), which had handled the social network's IPO. Noto served as a Managing Director in the Technology, Media and Telecom group at Goldman since October 2010 after having served as the CFO of the National Football League previously. MAJOR MOVERS: Among the notable gainers was Amicus Therapeutics (FOLD), which rose 23% following upgrades at Leerink and Janney Capital that came a day after the company provided updates on its potential monotherapy for Fabry patients. Also higher was Regeneron (REGN), which advanced 7% after Sanofi (SNY) disclosed in a regulatory filing that it plans to increase its beneficial ownership stake in its smaller pharmaceutical industry peer to 22.5% from 20.5%. Among the noteworthy losers was STAAR Surgical (STAA), which dropped 18% after it received a warning letter from the FDA following the regulator's inspection of a manufacturing plant. Also lower following its earnings reports was lighting solutions maker Acuity Brands (AYI), which fell 13% after its sales and profits missed expectations. INDEXES: Near midday, the Dow was up 134.80, or 0.8%, to 16,961.40, the Nasdaq was up 50.88, or 1.15%, to 4,459.06, and the S&P 500 was up 13.62, or 0.69%, to 1,973.85.
News For NFLX;TWTR;AYI;FOLD;REGN;SNY;STAA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
October 20, 2014
11:37 EDTTWTRStocks with call strike movement; X TWTR
Subscribe for More Information
10:37 EDTSNYSanofi unit announces Aubagio gains FDA approval due to study data
Genzyme, a Sanofi company, announced that the Food and Drug Administration has approved the inclusion of efficacy and safety data from the TOWER and TOPIC studies of once-daily, oral Aubagio in the productís U.S. label. In the TOWER study, patients with relapsing MS receiving Aubagio 14 mg had a statistically significant reduction in annualized relapse rate and relative risk of sustained disability progression compared to placebo. In addition, a significant reduction in annualized relapse rate was observed in patients treated with Aubagio 7 mg compared to placebo. The TOPIC study was designed to assess whether initiation of Aubagio in patients who experienced their first neurological symptoms suggestive of MS could prevent or delay a second clinical attack. In this study, the proportion of patients free of relapse was statistically significantly greater for Aubagio 14 mg and 7 mg, compared to placebo. Results of the TOPIC study were published in The Lancet Neurology in September.
09:04 EDTAYIAcuity Brands builds engineering facility in Decatur, GA
Acuity Brands announced it will build an engineering and technology center at a site it owns in Decatur, Georgia, and will invest in facility upgrades at its complex in Conyers Georgia, as part of a plan to enhance a workplace that will drive innovation and technology advances. In the Decatur project, the Company will retrofit an existing 167,000 square-foot building to become its new Engineering and Technology Center. The building, located at One Lithonia Way, will undergo a total transformation that will incorporate leading workplace design, technology and systems into the new facility. The goal is to continue to provide and accelerate an open work environment that enhances collaboration, sparks innovation, and helps associates bring new technologies even more quickly to market. The $11 million project will begin immediately, with completion scheduled for mid-2015. Acuity Brands will relocate approximately 200 software and electrical engineers, technologists and support staff to the new Decatur facility from its Conyers location once construction is completed. In Conyers, beginning later this year and over the next several years, Acuity Brands will make significant investments in redesigning and retrofitting the four main buildings on its campus to include open workspace design, new infrastructure and enabling technologies, as well as new furnishings.
08:06 EDTSNYMerck, Sanofi unit announce pediatric hexavalent vaccine BLA
Subscribe for More Information
07:19 EDTSNYIBC Life Sciences to hold a conference
Subscribe for More Information
07:16 EDTSTAA, REGNAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
07:10 EDTREGN, FOLD, SNYAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:02 EDTREGN, SNYRegeneron Sanofi begins dosing in Phase 3 study of dupilumab
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis, or AD, that is not adequately controlled with topical AD medications. LIBERTY AD CHRONOS, the first trial in the Phase 3 clinical program for dupilumab, is a randomized, double-blind, placebo-controlled, multi-national study with the primary objective of demonstrating the efficacy of dupilumab in adults with moderate to severe AD when administered concomitantly with topical corticosteroids through 16 weeks.
06:01 EDTNFLXStocks with implied volatility below IV index mean; EBAY NFLX
Stocks with implied volatility below IV index mean; eBay (EBAY) 27, Netflix (NFLX) 40 according to iVolatility.
October 19, 2014
19:46 EDTFOLDAmicus announces additional positive data from from Fabry monotherapy study
Subscribe for More Information
October 17, 2014
16:55 EDTNFLXStocks end volatile week lower amid oil price plunge
Subscribe for More Information
16:01 EDTTWTROptions Update; October 17, 2014
iPath S&P 500 VIX Short-Term Futures down 1.75 to 38.58 Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX GILD CLF PBR according to Track Data.
12:38 EDTNFLXNetflix shares 'so far underpriced right now its amazing,' says Cuban
Subscribe for More Information
12:17 EDTTWTR, NFLXMark Cuban says buying Netflix shares, sees company as M&A target
Subscribe for More Information
11:38 EDTNFLXCuban say buying Netflix stock, predicts 'someone will try to buy them'
Subscribe for More Information
10:58 EDTNFLXHBO streaming service may cost around $15 a month, The Information reports
Subscribe for More Information
09:38 EDTTWTR, NFLXActive equity options trading on
Subscribe for More Information
09:06 EDTREGN, SNYAmgen files patent infringement lawsuit against Sanofi, Regeneron
Amgen (AMGN) announced that it filed a lawsuit in the United States District Court of Delaware against Sanofi (SNY), Aventisub, formerly doing business as Aventis Pharmaceuticals, and Regeneron Pharmaceuticals (REGN) for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, or PCSK9. By its complaint, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced that they have completed Phase 3 clinical trials on alirocumab and intend to pursue regulatory approval to market alirocumab in the U.S. Amgen previously announced submission of a Biologics License Application to the FDA for evolocumab, its own investigational human monoclonal antibody to PCSK9, for the treatment of high cholesterol, on Aug. 28.
07:07 EDTREGNRegeneron announces EYLEA results from NIH study
Subscribe for More Information
06:24 EDTNFLXStocks with implied volatility below IV index mean; HPQ NFLX
Stocks with implied volatility below IV index mean; HP (HPQ) 31, Netflix (NFLX) 40 according to iVolatility.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use